You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Bal Pharma hits the roof on launching favipiravir formulation

Capital Market 

Bal Pharma hit an upper circuit of 5% at Rs 98.40 after the company announced the launch of favipiravir formulation into Indian market, under the brand name BALflu.

Favipiravir is an emerging anti-viral drug used for patients with mild to moderate COVID-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.

BALflu (favipiravir) is a broad-spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, filovirus, west nile virus, food & mouth disease virus and lassa virus.

The drug has been approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with a recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14. It has been made available across all the major markets in India as a prescription drug.

Shailesh Siroya, managing director of the company, speaking at the launch of the product has said that the BALflu has the efficacy to clear the virus faster by 28.7% and is marketed at a very affordable price of Rs 85 per tablet, so as to enable the needy patients to access this drug on time.

Bal Pharma is a pharmaceutical company, specialized in prescription drugs, generic & OTC products, intravenous infusion and bulk actives.

The company reported a consolidated net profit of Rs 0.32 crore in Q3 FY21 compared with net loss of Rs 3.57 crore in Q3 FY20. Net sales rose 46% YoY to Rs 63.03 crore during the quarter.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 25 2021. 09:22 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU